Please provide your email address to receive an email when new articles are posted on . Postmenopausal women experienced more widespread vertebral bone accrual at the lumbar spine at 12 months of ...
Amgen AMGN and UCB UCBJF announced top-line results from the phase III multi-center, international, randomized, double-blind, placebo-controlled, parallel-group FRActure study in postmenopausal woMen ...
In this article, I have categorized osteoporosis drugs into two types: bone resorption inhibitors that stop bone breakdown, ...
Boston — The investigational agent romosozumab significantly promoted bone-mineral density (BMD) at the hip and spine compared with teriparatide (Forteo, Lilly), a parathyroid hormone (PTH) 1-34 ...
Please provide your email address to receive an email when new articles are posted on . The Endocrine Society updated its osteoporosis clinical practice guideline to include recommendations for ...
Romosozumab significantly increases bone mineral density and bone content compared with teriparatide
A new study shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also ...
AUSTIN, Texas – One year of romosozumab (Evenity) followed by 1 year of denosumab (Prolia, Xgeva) was associated with improved bone mineral density (BMD) and lower fracture incidence compared with 2 ...
The investigational humanized monoclonal antibody romosozumab (Amgen and UCB Pharma) increases bone mineral density (BMD) and bone formation and reduces bone resorption in postmenopausal women with ...
THOUSAND OAKS, Calif. and BRUSSELS, Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from several exploratory analyses of the Phase 2 study ...
In postmenopausal women with osteoporosis, prior fracture, and type 2 diabetes, 12 months of romosozumab significantly improved bone strength when combined with alendronate, compared with alendronate ...
THOUSAND OAKS, Calif. and BRUSSELS, Feb. 22, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced top-line results from the Phase 3 placebo-controlled FRActure ...
(HealthDay)—In an Endocrine Society guideline update, published online in the March issue of the Journal of Clinical Endocrinology & Metabolism, recommendations are presented for the use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results